CARsgen Therapeutics (HKG:2171) recorded positive results for the confirmatory phase 2 clinical trial of Satri-cel, a candidate drug for the treatment of gastric, gastroesophageal junction, and pancreatic cancer, a Monday Hong Kong bourse filing said.
The study evaluated the safety and efficacy of satricabtagene autoleucel or satri-cel, CT041 in patients with advanced gastric or gastroesophageal junction cancers.
The study, including the assessment by the Independent Review Committee, showed an elevated progression-free survival rate for the patients treated with satri-cel compared to other treatment choices in the market.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.